SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
60409:23 ET CELG Celgene: negative report from Avalon (23.61) We're hearinDoc Bones-12/4/2002
603Celgene Corporation Advances First JNK Inhibitor Into Phsim1-10/21/2002
602Thursday June 27, 4:13 pm Eastern Time Press Release SOURCE: Noven PharmaceuticaMiljenko Zuanic-6/27/2002
601Tuesday June 11, 8:36 am Eastern Time Press Release SOURCE: Celgene Corporation Miljenko Zuanic-6/11/2002
600Agree. Hear that Novartis is looking for large supplier for the active ingredieMiljenko Zuanic-6/6/2002
599This is big news for celg. They earn a substantial royalty on this, which as I rkrw-6/6/2002
598FDA Grants Marketing Clearance for Ritalin LA, A Once-Daily Formulation of Ritalsim1-6/6/2002
597Tuesday May 21, 7:58 am Eastern Time Reuters Company News Celgene to start renasim1-5/21/2002
596Clinical Trial Results Reported at ASCO on the Use of THALOMID(R) in Metastatic sim1-5/21/2002
595Clinical Data on THALOMID(R) in Combination With Irinotecan In Colorectal Cancersim1-5/21/2002
594Celgene Delays Filing for Thalomid Drug Approval (Update4)sim1-3/8/2002
593Celgene Corp. To Seek FDA Mktg OK For Thalomid DOW JONES NEWSWIRES WARREN, N.Jmopgcw-3/7/2002
592Results don't seem to have been widely anticipated - finance.yahoo.com WARRnigel bates-1/30/2002
591>>WARREN, N.J., Dec 21 (Reuters) - Biotech company Celgene Corp. (NasdaqNMtuck-12/21/2001
590Investigators Report Revimid(TM) Demonstrates Anti-Tumor Activity in Phase I/II sim1-12/11/2001
589Over Fifty-five Abstracts on THALOMID and REVIMID in All Stages of Several Hematnigel bates-12/7/2001
588Definitely, were smart move from CELG when they bought Signal. MiljenkoMiljenko Zuanic-11/26/2001
587Proc. Natl. Acad. Sci. USA, Vol. 98, Issue 24, 13681-13686, November 20, 2001 Stnsaf-11/26/2001
586Celgene Corporation and Weill Cornell Initiate Research Program to Evaluate The nigel bates-11/20/2001
585Apologies for missing Greek symbols... 15 November 2001 Nature 414, 308 - 313 nigel bates-11/16/2001
584WARREN, N.J., Nov. 16 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG - news) nigel bates-11/16/2001
583Novel Celgene JNK Inhibitors Significantly Enhance Survival in Preclinical Modelnigel bates-11/12/2001
582THALOMID(R) Clinical Trials To Be Discussed At Chemotherapy Foundation Symposiumsim1-11/7/2001
581Celletech is trying hard to penetrate ADD market. Will be interesting to learn aMiljenko Zuanic-10/25/2001
580From Briefing, don't know if this news is already priced in or not, no posittom pope-10/18/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News